surmount-1 tirzepatide trial obesity without diabetes A 72-week trial compared the two leading GLP-1 medications in adults with obesity (no diabetes). Shifts in body mass index

Molecules 27 , 5252 (2022)

more research is needed to identify disease-modifying treatments and, ultimately, curative therapies

Beyond the initial approvals (FDA 2017, EMA 2018), real-world evidence confirms the clinical benefits of semaglutide, while ongoing post marketing has thus far revealed no unexpected safety signals

It can raise the chance of low blood sugar, especially when taken with other diabetes drugs

weight loss becomes an uphill battle because the body is trying to maintain what it believes to be its ideal weight, called a weight set point

Letter: Concentrations of serum iron in relation to infection in the neonate